DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT07448519

CompletedPhase NA

Colonic Delivery of DIM and Perilla Oil on Gut Hormones and Food Intake in Obesity

The Effect of Targeted Food Supplements on Gut Hormone Levels

Asset

GLP-1 / incretin class catch-all

Listed sites

1

Recruiting sites

—

Enrollment

20

actual

Study population

Obesity / overweight

Key I/E criterion

•BMI 30-40

Primary endpoint

•Circulating levels of appetite-regulating gut hormones (PYY, GLP-1, ghrelin)

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT07448519
Org study IDQMREC23.061
Secondary ID10028205Innovate UK

Timeline

Milestones

Study start2023-06-13actual
Primary completion2023-08-02actual
Study completion2023-08-02actual
Study first posted2026-03-04actual
Last update posted2026-03-24actual

Assets

Investigational agents

GLP-1 / incretin class catch-all

Study populations

Who this study enrolls

Obesity / overweight

Eligibility

Who can enroll

Minimum age18 Years
Maximum age60 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•Obese but otherwise healthy volunteers aged between 18 and 60 years, of either sex
•Body Mass Index (BMI) of 30-40 kg/m²
•Agreement to eat the scheduled meals
•Ability to understand the study information sheet and instructions in English, and able to provide informed consent

Exclusion criteria

•Not meeting any of the inclusion criteria above
•Major gut surgery involving removal of any part of the gastrointestinal tract
•Known major bowel disease
•Currently taking medication for diabetes (Type 1 or Type 2)
•Currently taking medication for weight loss

Endpoints (3)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Patient-reported / QoL
1
Safety / tolerability / PK
1
Other (unclassified)
1

Patient-reported / QoL

1 endpoint
Secondary/protocol endpoint

Subjective hunger and appetite ratings using visual analogue scales (VAS)

Time frame:Baseline and during each study visit (Visit 1 and Visit 2), every 30 minutes from 08:00h to 16:00h.

descriptive, improvement

Safety / tolerability / PK

1 endpoint
Other/protocol endpoint

Safety and tolerability of lower gut-targeted nutrient capsules

Time frame:During each study visit and for 24 hours post-capsule ingestion.

Treatment-emergent AEs (any)

descriptive

Other (unclassified)

1 endpoint
Primary/protocol endpoint/low confidence

Change in circulating levels of appetite-regulating gut hormones (PYY, GLP-1, ghrelin)

Time frame:Single day during each study visit (Visit 1 and Visit 2), with measurements every 30 minutes from 08:00 to 16:00.

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.